Suchergebnisse - "Armuzzi, Alessandro"

PubPharm (45)

1

Cardiovascular Safety of Ozanimod in Patients With Ulcerative Colitis : True North and Open-Label Extension Analyses

enthalten in: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association | 2024

von Armuzzi, A. | Cross, R. | Lichtenstein, G. | +12

2

The first international Rome consensus conference on gut microbiota and faecal microbiota transplantation in inflammatory bowel disease

enthalten in: Gut | 2023

von Lopetuso, L. | Deleu, S. | Godny, L. | +22

3

Clostridium difficile Infection in Patients with Ulcerative Colitis Treated with Tofacitinib in the Ulcerative Colitis Program

enthalten in: Inflammatory bowel diseases | 2023

von Loftus, E. | Baumgart, D. | Gecse, K. | +7

4

Comparative Risk of Serious Infections With Biologic Agents and Oral Small Molecules in Inflammatory Bowel Diseases : A Systematic Review and Meta-Analysis

enthalten in: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association | 2023

von Solitano, V. | Facciorusso, A. | Jess, T. | +6

5

Dysfunctional Extracellular Matrix Remodeling Supports Perianal Fistulizing Crohn's Disease by a Mechanoregulated Activation of the Epithelial-to-Mesenchymal Transition

enthalten in: Cellular and molecular gastroenterology and hepatology | 2023

von Rizzo, G. | Rubbino, F. | Elangovan, S. | +22

CommentIn: Cell Mol Gastroenterol Hepatol. 2023;15(3):801-802. - PMID 36586719

6

Predictors of Sustained Response With Tofacitinib Therapy in Patients With Ulcerative Colitis

enthalten in: Inflammatory bowel diseases | 2022

von Sandborn, W. | Armuzzi, A. | Liguori, G. | +6

7

Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease : the IG-IBD LIVE study

enthalten in: Alimentary pharmacology & therapeutics | 2022

von Pugliese, D. | Privitera, G. | Crispino, F. | +58

CommentIn: Aliment Pharmacol Ther. 2022 Aug;56(4):731-732. - PMID 35879894

8

Higher vs Standard Adalimumab Induction Dosing Regimens and Two Maintenance Strategies : Randomized SERENE CD Trial Results

enthalten in: Gastroenterology | 2022

von D'Haens, G. | Sandborn, W. | Loftus, E. | +19

CommentIn: Gastroenterology. 2022 Jun;162(7):1831-1832. - PMID 35364063

9

Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST) : an open-label, multicentre, randomised phase 3b trial

enthalten in: The lancet. Gastroenterology & hepatology | 2022

von Danese, S. | Vermeire, S. | D'Haens, G. | +99

CommentIn: Lancet Gastroenterol Hepatol. 2022 Apr;7(4):276-277. - PMID 35120657

10

Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA) : a randomised, double-blind, double-dummy, phase 3 study

enthalten in: The lancet. Gastroenterology & hepatology | 2022

von Danese, S. | Colombel, J. | Lukas, M. | +114

CommentIn: Lancet Gastroenterol Hepatol. 2022 Jan;7(1):2-4. - PMID 34798035

1
2
3
4
5
Nächster »
[5]